EGFR and non-small cell lung carcinoma: The PSA illustrated the probability of the cost-effectiveness advantage of osimertinib was 46.4% when WTP was $37,663.26/QALY, suggesting that the first-line treatment of osimertinib for previously untreated advanced NSCLC with EGFR-positive mutation was still not cost-effective as compared to the first-generation EGFR-TKI.